Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 - Pipeline Review, H1 2020

March 2020 | 32 pages | ID: GA3600266DCDEN
Global Markets Direct

Abstracts

Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 - Pipeline Review, H1 2020

SUMMARY

Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) pipeline Target constitutes close to 5 molecules. The latest report Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 - Pipeline Review, H1 2020, outlays comprehensive information on the Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Gamma-aminobutyric acid receptor subunit alpha-3 is a protein that in humans is encoded by the GABRA3 gene. It mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 2 and 1 respectively. Report covers products from therapy areas Central Nervous System and Dermatology which include indications Anxiety Disorders, Epilepsy, Neuropathic Pain (Neuralgia), Depression, Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), Fibromyalgia (Fibromyalgia Syndrome) and Pruritus.

Furthermore, this report also reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3)
• The report reviews Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) targeted therapeutics and enlists all their major and minor projects
• The report assesses Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Overview
Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Companies Involved in Therapeutics Development
Baergic Bio Inc
Cerevel Therapeutics LLC
NeuroCycle Therapeutics Inc
Saniona AB
Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Drug Profiles
BAER-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVL-865 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCT-10004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAN-711 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GABR for Neuropathic Pain and Fibromyalgia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Dormant Products
Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Discontinued Products
Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Product Development Milestones
Featured News & Press Releases
Dec 08, 2019: Cerevel Therapeutics announces phase 1 results for CVL-865, a Novel a2/3/5-subtype GABAA Positive Allosteric Modulator in Development to treat Epilepsy
Nov 25, 2019: Cerevel Therapeutics to present safety, tolerability, and pharmacokinetics results from phase 1 trial of CVL-865
Apr 09, 2019: Cerevel Therapeutics announces publication of phase 2a study results in Neurology on its most advanced investigational Epilepsy treatment
Feb 18, 2019: Sanionas SAN711 selected for clinical studies in itching and pain
Feb 13, 2019: NeuroCycle Therapeutics receives NIH SBIR Grant to study Dravet Syndrome drug candidate NCT10004
Dec 04, 2017: Saniona Selects Preclinical Candidate in GABAA a2/a3 Program for Neuropathic Pain and Chronic Itching
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Baergic Bio Inc, H1 2020
Pipeline by Cerevel Therapeutics LLC, H1 2020
Pipeline by NeuroCycle Therapeutics Inc, H1 2020
Pipeline by Saniona AB, H1 2020
Dormant Projects, H1 2020
Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020

COMPANIES MENTIONED

Baergic Bio Inc
Cerevel Therapeutics LLC
NeuroCycle Therapeutics Inc
Saniona AB